SCHEMBL7024433

SCHEMBL7024433

C[C@H](Nc1nc(-c2ccc3ccccc3c2)cc(-n2cnc3ccccc32)n1)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.62
JAK2 O60674 4/20 0.51
JAK3 P52333 4/20 0.51
ATP1A1 P05023 1/20 0.47
ATP1B1 P05026 1/20 0.47
ATP1A3 P13637 1/20 0.47
ATP1B2 P14415 1/20 0.47
ATP1A2 P50993 1/20 0.47
ATP1B3 P54709 1/20 0.47
FXYD2 P54710 1/20 0.47
ATP1A4 Q13733 1/20 0.47
AURKA O14965 1/20 0.46
AURKB Q96GD4 1/20 0.46
MKNK1 Q9BUB5 2/20 0.45
MKNK2 Q9HBH9 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014868 0.91 LCK (0.69) LCKJAK2JAK3AURKAAURKB
SCHEMBL7021040 0.89 LCK (0.64) LCKJAK2JAK3AURKAAURKB
SCHEMBL7023496 0.88 LCK (0.62) LCKJAK2JAK3AURKAAURKB
SCHEMBL7021158 0.87 LCK (0.58) LCKJAK2JAK3AURKAAURKB
SCHEMBL7025640 0.86 LCK (0.60) LCKJAK2JAK3AURKAAURKB
SCHEMBL7028475 0.85 LCK (0.59) LCKJAK2JAK3ATP1A1ATP1B1
SCHEMBL7105532 0.84 LCK (0.60) LCKJAK2JAK3AURKAAURKB
SCHEMBL7100716 0.84 LCK (0.63) LCKJAK2JAK3AURKAAURKB
SCHEMBL7100712 0.84 LCK (0.63) LCKJAK2JAK3AURKAAURKB
SCHEMBL7105538 0.84 LCK (0.60) LCKJAK2JAK3AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed